首页 | 本学科首页   官方微博 | 高级检索  
     


Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS
Authors:Shin J Oh MD  Natalya Shcherbakova MD  Anna Kostera‐Pruszczyk MD  PhD  Mohammad Alsharabati MD  Mazen Dimachkie MD  Jose Munoz Blanco MD  Thomas Brannagan MD  Dragana Lavrnić MD  PhD  Perry B Shieh MD  PhD  Christophe Vial MD  Andreas Meisel MD  Samuel Komoly MD  PhD   DSc  Benedikt Schoser MD  Kumaraswamy Sivakumar MD  Yuen So MD  PhD  LEMS Study Group
Affiliation:1. Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA;2. Research Center of Neurology, Moscow, Russia;3. Department of Neurology, Medical University of Warsaw, Poland;4. University of Kansas Medical Center, Kansas City, Kansas, USA;5. Gregorio Maranon Hospital, Madrid, Spain;6. Columbia University Medical Center, New York, New York, USA;7. Clinical Center of Serbia, Clinic of Neurology, Belgrade, Serbia;8. Department of Neurology, University of California, Los Angeles, California, USA;9. Hospital of Lyon, ENMG Service and Neuromuscular Pathology Hospital, Lyon, France;10. Charite Universitatsmedizin Berlin‐NeuroCure Clinical Research Center, Berlin, Germany;11. University of Pécs, Department of Neurology, Pécs, Hungary;12. Ludwig‐Maximilians‐University Munich Friedrich‐Baur‐Institute, Munich, Germany;13. Neuromuscular Research Center, Phoenix, Arizona, USA;14. Stanford University, Stanford, California, USA
Abstract:
Keywords:Amifampridine phosphate  3,4‐diaminopyridine  3,4‐DAP  Lambert‐Eaton myasthenic syndrome  LEMS  Potassium channel blockers  Small cell lung cancer (SCLC)
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号